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Abstract
Agents that damage our DNA are omnipresent in our environment and inside
our cells themselves. Left unrepaired, DNA damage can lead to premature aging,
neurodegeneration and cancer. Humans have thus evolved intricate and widespread
mechanisms to repair and manage this damage. These mechanisms-called the DNA
damage response-often involve cell cycle arrest. Cell cycle arrest gives the cells
precious extra time to utilize its diverse set of repair pathways. Among these is the
homologous recombination pathway, which repairs DNA double-strand breaks.
When the damage is deemed irreparable, a cell can choose to die: this allows for the
maintenance of genomic integrity of the organism.
Humans share 99.9% of the same genetic information. The remaining 0.1% is
responsible for all genetic variations between individuals. This includes differences
in disease susceptibility. In this study, we examined the inter-individual differences
in the DNA damage response. To do so, we used a panel of twenty-four B
lymphoblastoid cell lines derived from twenty-four healthy individuals of diverse
ancestries. This panel had already been shown to display a broad range of
sensitivity to several DNA damaging agents.
We focused our attention on the alkylating agents temozolomide and
methylnitronitrosoguanidine (MNNG). While MNNG has been extensively studied as
a model DNA damaging drug, temozolomide is used in the clinic today to treat
astrocytoma and glioblastomas. The two drugs are often referred to as functional
analogues. We wanted to see if the cell lines' relative sensitivities to both drugs
would be similar, which would support the analogy made between the drugs, or
different, which would refute it. Furthermore, we measured the amounts of sister
chromatid exchanges (SCEs) induced by temozolomide treatment to determine if
the sensitivity measured by growth inhibition post-treatment was correlated with
the amount of temozolomide-induced SCEs. For the cell lines tested, we found that
the MNNG-induced sensitivity was similar to that induced by temozolomide. We also
found a cell line in which temozolomide induced a large growth inhibition, all the
while inducing no detectable SCEs.
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Title: Professor of Biological Engineering and Biology, Director, Center for
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Acknowledgments
First and foremost, I would like to thank my advisor, Professor Leona
Samson, for her support and guidance over the past years. I am very grateful to have
been given such an exciting project to work on.
Besides providing excellent opportunities for research, the Biological
Engineering department has provided me with excellent classes and great
professors. These professors have mentored me throughout my Master of Science
degree, and I am particularly grateful for the help and support of Douglas
Lauffenburger, our department head.
I would like to thank past and present members of the Samson lab. Whether
it be by teaching me new experimental techniques, by helping me with my project
design, or just by being supportive friends, they have tremendously helped me with
this project, and made the Samson lab a truly collaborative and fun place to work.
I would like to acknowledge the Koch Institute flow cytometry facility where
all the flow cytometry data were obtained. I would especially like to thank Glenn
Paradis for training me and helping me troubleshoot my flow cytometry
experiments.
Last but definitely not least, I would like to thank my friends and family. My
friends at MIT-and particularly the ones in the Biological Engineering
department-have made MIT a fun place to work, and continue to give our
department a fun and unique flavor. My parents and sister have been
unconditionally supportive during these past two years, and I would be lost in the
world without their emotional support, great practical advice, and overall
dedication.
Table of Contents:
bA stracS ...C... ......................................................................mMEN mom
A cknow ledgm ents ............................................................ . 2
Figures and Tables ...............................................................
Introduction............. ..... E.. E. .m .m . ... .. .m . m. .. E. .. .. E. . . e. 5
1. DNA damage and the DNA damage response................................................................. 5
2. The Cell decision process....................................................................................................... 8
3. Of inter-individual differences and personalized therapies .................................... 8
4. Experimental system used to study the DDR in different individuals................. 11
Temozolomide, MNNG, and the DNA damage response they initiate:.............................11
T h e C oriell p an el o f cell lin es:.................................................................................................................16
5. Goal of the study and project design.............................................................................. 16
Results and Discussion................................................17
1. A high-throughput growth inhibition assay is used to measure temozolomide
and MNNG induced cytotoxicity and cell cycle effect..................................................... 17
In tro d u ctio n : .................................................................................................................................................. 1 7
R esu lts & D iscu ssio n :.................................................................................................................................. 2 1
2. Sister chromatid exchange assay ..................................................................................... 27
In tro d u ctio n : .................................................................................................................................................. 2 7
R esu lts an d D iscu ssio n : ............................................................................................................................. 3 3
M aterials and M ethods.................. .. . ... ... EKE E.. E. E. .M 3 6
1. T issu e Cu ltu re............................................................................................................................. 36
2. Flow cytometry based growth inhibition assay .......................................................... 38
T em ozolom id e treatm ent:........................................................................................................................ 38
M N N G tre atm en t: ......................................................................................................................................... 3 8
B rd U a d d tio n .................................................................................................................................................. 3 9
Sam p le p rep aration for FAG S .................................................................................................................. 39
D a ta C o lle ctio n ............................................................................................................................................... 4 0
D a ta A n a ly sis .................................................................................................................................................. 4 0
3. Sister Chromatid Exchange assay .................................................................................. 41
T em ozolom id e treatm ent ......................................................................................................................... 4 1
O btain ing m etaphase sp reads ................................................................................................................ 4 1
H arlequin staining of chrom osom es ............................................................................................. 42
M icroscopy an d im age analysis.............................................................................................................. 43
Conclusions and Future Directions ............................. 44
Figures and Tables
Figure 1: The effects of DNA dam age on a cell........................................................................ 7
Figure 2: A panel of 24 cell lines derived from 24 healthy individuals of diverse ancestry
shows a broad range of sensitivity to MNNG and MMS........................................................10
Figure 3: Temozolomide undergoes spontaneous conversion under physiological
conditions to the active alkylating agent M TIC......................................................................... 13
Figure 4: Chem ical structure of M NNG ................................................................................. 13
Figure 5: MGMT is a direct reversal enzyme that can remove methyl adducts created by
tem ozolom id e or M N N G ................................................................................................................ 14
Figure 6: Models of mismatch repair dependent cytotoxicity.............................................15
Figure 7: Experimental setup for the high-throughput growth inhibition assay used to
measure sensitivity of the Coriell panel of cell lines to MNNG and
te m o z o lo m id e ................................................................................................................................ 1 9
Figure 8: Schematic representation of what how Hoechst and PI allow us to determine what
cell cycle the nuclei are in, and in w hat phase...................................................................... 19
Figure 9: Flow cytometry data analysis methodology......................................................... 20
Figure 10: Survival curves for the 24 cell lines after temozolomide treatment................22
Figure 11: Survival curves for the 24 cell lines after MNNG treatment.............................23
Figure 12: Survival curves for the 24 cell lines after BCNU treatment...............................25
Figure 13: The high-throughput assay was able to capture the cell cycle effects of
tem ozolom ide or M NNG treatm ent on the cells..................................................................... 26
Figure 14: Pathways of DNA double strand break repair by homologous
reco m b in atio n...............................................................................................................................3 0
Figure 15: Schematic representation of BrdU incorporation into the DNA of replicating
c e lls ................................................................................................................................................. 3 1
Figure 16: Representative picture of a metaphase spread obtained with our SCE
a s s a y ............................................................................................................................................... 3 2
Figure 17: Induced sister chromatid exchanges for the 24 cell lines after temozolomide
tre a tm e n t........................................................................................................................................3 5
Table 1: Doubling times for all 24 cell lines, and approximated doubling times................37
Introduction
1. DNA damage and the DNA damage response
DNA damaging agents are omnipresent, whether it be in our environment, or
inside our bodies themselves. The exogenous sources of DNA damage include UV
radiation from sunlight, elements in our food and drinks, and chemical pollutants.
Some chemotherapeutic agents used in the clinic today to treat cancers also function
as DNA damaging agents. The endogenous sources of DNA damage are just as
varied. Our cells' metabolism, as well as their inflammatory responses generate
reactive oxygen species and reactive nitrogen species that can cause DNA lesions 78.
Furthermore, our cells also have to manage DNA's intrinsic chemical instability, as
well as its replication errors 2. In total, it is estimated that each of our cells is faced
with 105 DNA lesions each day. 6
Unrepaired DNA damage can have harmful consequences. At the cellular
level, it can lead to mutations, chromosomal aberrations, cell cycle delay or arrest,
and cell death 10. These effects have consequences at the organism level; they can
lead to cancer, premature aging, neurodegeneration, tissue toxicity and endothelial
damage 1 6.
In order to counteract DNA lesions, humans have evolved a very broad and
intricate response system-called the DNA damage response (DDR)-that is
triggered in our cells in the presence of damage. This response is initiated when
sensors detect damage; the signal is amplified through the recruitment of mediators
and then of transducers and effectors that lead to diverse cellular responses 12.
When a cell deems that the damage is too great, it can trigger its own cellular
death. If it does not die, a cell can arrest itself, thus providing crucial extra time for
the repair machineries to process the damage. If residual damage is left at the time
of DNA replication, mutations and chromosomal aberrations can arise. This can
eventually lead to cancer 1i (figure 1).
The types of damage that can occur in our DNA are diverse. As a
consequence, the DNA repair processes that our cells have evolved are also diverse.
Small DNA adducts can be removed through direct reversal by proteins like 06-
methylguanine-DNA methyltransferase 15 16. Base excision repair (BER) is also
solicited in the case of small, non-helix-distorting base lesions in the genome. In
BER, a DNA glycosylase recognizes the lesion, flips the damaged base out of the
double helix, and cleaves the N-glycosidic bond of the damaged base, leaving an
abasic site. DNA is then nicked at this site, and several enzymes are recruited to fill
and ligate the resulting DNA 1-. In the case of helix-distorting lesions or pyrimidine
dimers like the ones induced by UV damage, nucleotide excision repair (NER) often
comes into play. The enzymes involved in NER will successively recognize the
lesion, locally unwind the DNA, remove a single stranded stretch of 25-30
nucleotides, then fill and ligate the gap M. Homologous recombination is the process
by which cells repair double-strand breaks by using a homologous template 9 , while
in non-homologous end-joining, the break ends are directly ligated without the need
for a homologous templateto. Finally, a cell can call upon translesion synthesis, a
DNA damage tolerance process that allows the DNA replication machinery to
replicate past DNA lesions 21.
The effects and importance of all the varied signals initiated after DNA
damage are still not completely understood and are active areas of research. Several
genome-wide screens for genes conferring susceptibility for DNA damage have
revealed that the DNA damage response actually involves a great multitude of actors
and processes in the cell. These actors haven't all been fully characterized22 23.
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Figure 3: The effects of DNA damage on a cell
Adapted from 6
2. The Cell decision process
In a multicellular organism, the process by which some cells chose to die in
the presence of damage that is deemed irreparable is crucial for the maintenance of
that organism's genomic integrity. A cell that decides against death despite the
presence of damage can accumulate mutations or chromosomal aberrations, two
hallmarks of cancer 24 If the cells of an organism chose to die too frequently, it is
also detrimental, as it can lead to unwanted cell death and premature tissue aging25.
Many elements are known to factor into this decision, and experimental evidence
shows that it depends on the cell type and on the amount of damage.
The cell decision process is frequently deregulated in cancer. The p53 tumor
suppressor gene, called the "guardian of the genome", has been shown to be a
master player in this process. p53 is mutated in 50% of all cancers 26.
3. Of inter-individual differences and personalized therapies
Humans share 99.9% of the same genetic information. The genetic diversity
of the human race as we know it is contained in the remaining 0.1%. Learning about
the genetic difference between humans can be used to understand population
history, trace lineages, analyze natural selection trends, and-above all-to predict
disease susceptibility' .
The genetic variations in human populations are varied. A Single Nucleotide
Polymorphism (SNP) refers to a DNA sequence variation of a single nucleotide
within a sequence that is present in 1% or more of the population; over ten million
such variants have been identified and validated in the human population. A short
tandem repeat (STR) in DNA occurs when a pattern of two or more nucleotides is
repeated and the repeated sequences are directly adjacent to each other. In human
populations, a short tandem repeat polymorphism (STRP) occurs when homologous
STR loci differ in the number of repeats. There are currently over 10 000 published
STR sequences in the human genome. Finally, insertions or deletions of certain parts
of the DNA sequence in different individuals also contribute to human genetic
diversity 8 .
These genetic variations can have consequences at the level of the cell, and of
the whole organism. It is therefore not surprising that several of them have been
implicated in disease susceptibility, and in patient response to a number of
therapeutic drugs. Today however, only about 10% of labels for FDA-approved
drugs contain pharmacogenetic information29. In the case of cancer drugs, most of
these drugs are only efficient in a small fraction of patients. Patients generally have
to change drug treatment strategies several times before an efficient one is found, if
ever. In order to improve the success rate of these drugs, it is becoming clear that
treatment strategies must become more personalized U'. Beyond personalized
treatment, health care today is also aiming towards becoming increasingly capable
of predicting and preventing cellular dysfunction and disease 33 .
The DNA damage response is no exception to these inter-individual
variations. It has been shown that human populations display a broad range of
sensitivities to different DNA damaging agents 3 (figure 2).
Numerous single genetic variants have been directly linked to disease states.
For instance, this is the case for sickle-cell anemia, where a single base mutation is
responsible for the disease34 . However, an increasing body of work is revealing that
each inter-individual polymorphism usually only leads to very subtle variations in
the cell, if any. A systems-wide approach is therefore necessary to integrate all of the
variations between individuals, and infer their influence-as a whole-on cellular
and organism processes35 .
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4. Experimental system used to study the DDR in different
individuals
Temozolomide, MNNG, and the DNA damage response they initiate:
Temozolomide is a chemotherapeutic drug used in the clinic today. It can be
used for the treatment of Grade IV astrocytoma - an aggressive brain tumor, also
known as glioblastoma multiforme, as well as anaplastic astrocytoma. It has been
available in the US since August 1999, and in other countries since the early 2000s3 6
4
At physiologic pH, temozolomide is converted to the short-lived active
compound MTIC (3-methyl-(triazen-1-yl)imidazole-4-carboxamide). While MTIC can
react with cellular proteins, the cytotoxicity of MTIC is due primarily to the 06-
methylguanine (06MeG)and 3-methyladenine (3MeA) methylation adducts 3 (figure
3).
In the presence of temozolomide, cells activate their DNA damage response.
The first step in the repair process most notably involves the use of the 06-
methylguanine-DNA methyltransferase (MGMT) repair protein. MGMT is a direct
reversal suicide enzyme that directly removes methyl adducts from 06MeG DNA
bases 38 (figure 5). If replication occurs before a given 06MeG lesion has been
repaired, the replication machinery will mistake the guanine for an adenine and pair
it with a thymine, thus creating a mismatch. An accumulation of mismatches can
directly signal for cell death. If the cell decides to survive, and the mismatch repair
machinery does not process this error, the mismatch will lead to a permanent
mutation at the next round of replication. When the mismatch repair machinery
does attempt to repair the mismatch, it is believed that since the cell will remove the
newly synthesized one, ie the thymine; the mismatch repair machinery will again
pair a thymine with the 06MeG; this leads to a futile repair cycle where the damaged
base never gets removed39 . This cycling eventually leads to replication fork collapse
and double strand breaks. Finally, double strand breaks can also signal for cell
death, or be processed through homologous recombination -IQM. (figure 6)
Methylnitronitrosoguanidine (MNNG) is a biochemical tool used
experimentally as a carcinogen and mutagen - (figure 4). Its cytotoxicity is also
primarily due to the 06MeG and 3MeA adducts, and MGMT is also strongly solicited
in response to MNNG induced damage. As a consequence, MNNG is often used as a
functional analogue of temozolomide 01-5. While the main cytotoxic lesions of
MNNG are the same as those of temozolomide, the other effects that both drugs have
on a cell could very well be different, and make the overall sensitivity of a given cell
line to each drug different.
For these reasons, we decided to investigate the DNA damage response to
temozolomide and to MNNG in different individuals.
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The Coriell panel of cell lines:
We focused our attention on a panel of twenty-four genetically diverse cell
lines. These twenty-four cell lines are a subset of a larger set of 450 B
lymphoblastoid cell lines; the subset maintains the diversity of the larger set 46. All
of them were derived from the blood of healthy United States citizens with
ancestries from around the globe. B lymphocytes were purified from the blood
samples, and then immortalized by Epstein Barr Virus (EBV) transformation. Since
EBV transformation does not affect p53 function, it is a reasonable assumption that
the DNA damage response in these cell lines is a mirror of what it is in the different
individuals. 4
Previous work conducted by Samson and colleagues has shown that these
cell lines display a broad range of sensitivity to the DNA alkylating agents MNNG
(figure 2). Using computational machine learning techniques, they successfully
identified 48 genes with basal expression that predicts susceptibility with 94%
accuracy. This leads us to believe that the panel of twenty-four cell lines is a good
experimental system to pursue studies on inter-individual differences in the DNA
damage response 3.
5. Goal of the study and project design
The goal of this thesis was to i) measure the sensitivity of the panel of twenty
four cell lines to the cytotoxic agents temozolomide and MNNG using a high-
throughput growth inhibition assay developed in the Samson laba; ii) in the case of
temozolomide, also measure the drug's induction of SCEs-a surrogate marker for
homologous recombination events, in order to compare this data to the growth
inhibition data.
Results and Discussion
1. A high-throughput growth inhibition assay is used to
measure temozolomide and MNNG induced cytotoxicity and
cell cycle effect.
Introduction:
Temozolomide and MNNG are two alkylating agents that are often used
interchangeably in the scientific community as they are thought to be analogues.
Their main cytotoxic lesions are 3MeA at the 06MeG (figures 3 and 4). However,
they also react with the proteins of a cell, and these reactions could be different for
both drugs. Furthermore, these drugs could have differing cytotoxicity kinetics. As a
consequence, a given individual may have differing sensitivities to both drugs.
To investigate this possibility, we worked with a panel of twenty-four cell
lines derived from twenty-four United States individuals. Previous work on these
cell lines from the Samson lab has revealed that they display a very broad range of
sensitivity to MNNG. It has also been shown that a cell line that is very resistant to
one source of damage can be sensitive to another. We wanted to determine i) if the
24 cell lines display as broad of a range of sensitivity to temozolomide as they do to
MNNG and ii) if the order of the cell lines in this range is the same for both drugs.
We used a high-throughput growth inhibition assay for measuring the
sensitivity of the cells. This assay was developed in the Samson lab, and has a
dynamic range comparable to that of the slower clonogenic survival assay, the
current gold standard for assessing cellular growth inhibition after DNA damage5 . In
the high-throughput method, BrdU-a thymidine analog-is added to the media of
cells. As the cells proliferate, they incorporate the BrdU into the A-T rich regions of
their DNA. Hoechst, a dye that preferentially binds AT-rich regions in the DNA, is
quenched by BrdU. Cells that have divided zero, one or two times in the presence of
BrdU can therefore be differentiated based on the level of quenched Hoechst
fluorescence, thus giving a measure of cell proliferation.
After cells were treated with temozolomide or MNNG, they were allowed to
recover for the duration of two doubling times, and then left to proliferate in the
presence of BrdU for another two doubling times (as shown in figure 7). The cells
were subsequently lysed to extract their nuclei and stained with Hoechst dye and
propidium iodide (PI). Figure 8 illustrates how this experimental set up allowed us
to distinguish first cell cycle nuclei from second and third cell cycle nuclei, as well as
G1 phase nuclei from S/G2 phase nuclei. The PI and Hoescht fluorescence of the
nuclei were measured by flow cytometry. Figure 9 shows the kinds of plots we
obtained, and how the data was gated and analyzed. The relative growth inhibitions
of treated samples versus mock treated samples give reproducible measures of the
sensitivity of the cells to treatment.
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Figure 7: Experimental setup for the high-throughput growth inhibition
assay used to measure sensitivity or the Coriell panel of cell lines to MNNG
and temozolomide
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Figure 9: Flow cytometry data analysis methodology (adapted from )
Panels a. b and c show how we filtered the raw data:
a) Side scatter vs. forward scatter plot shows the position of nuclei, chicken erythrocyte
nuclei (CEN) and the debris. We start by excluding the debris by creating gate R1
b) These are the events in gate R1. In this PI-Height vs. PI-Area plot, the events that fall
below the drawn diagonal must be excluded, as the correspond to cell doublets that cannot
be taken into account in our analysis.
c) These are the events in gate R2; PI-Area vs. Hoechst-Area of these events is plotted.
During data acquisition, PI and Hoechst channel voltages were adjusted to position the CEN
at (30K, 30K)
Panels d. e and f show how we gated the filtered data (PI-Area vs. Hoechst-Area plots
d) The light grey area is where the nuclei in the first cell cycle would fall, the dark grey is
where the ones in their second cell cycle would fall, and finally the one in black is where the
third cell cycle nuclei would fall.
e) This plot shows the G1, S and G2 populations for each cell cycle.
f) Example of a sample for which the CEN and cell cycle gates have been drawn.
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Results & Discussion:
1. Results with the TK6 cell line
We treated our cells with MNNG or temozolomide. We used a dose range of 0
to 480 [M for temozolomide and 0 to lpg/mL for MNNG (figures 10 and 11). Both of
these drugs' main cytotoxic lesions are 06MeG and 3MeA. A frontline repair pathway
used by cells to repair the induced damage is direct removal of the methyl adducts
with the suicide repair protein 06-methylguanine-DNA methyltransferase (MGMT).
It has previously been reported that cells lacking MGMT are particularly sensitive to
such alkylating agents 48. It is therefore not surprising that the B lymphoblastoid cell
line TK6, which also lacks MGMT, is extremely sensitive to both drugs.
2. Dynamic range
With the dose ranges used (ie 0-480ptM for temozolomide and 0-1pg/mL for
MNNG), the growth inhibition dose-response curves for our twenty-four
lymphoblastoid cell lines from twenty-healthy individuals of diverse ancestry span
two logs. This is very large, and in the case of temozolomide-where all twenty-four
cell lines were assayed-allows us to partition the cell lines into three groups: i) the
very resistant cell lines, from most resistant to least resistant: cell lines #7, 3,16 and
14, ii) the mildly sensitive cell lines, # 21, 22, 6, 8, 13, 12, 19, 23, 17, 1, and 20, and
iii) the very sensitive cell lines, # 9, 11, 5, and 4. This ranking is based on their
sensitivity at the 480 pM. At the 0.5[tg/mL dose for MNNG, which is approximately
equivalent to the 480 p.M dose of temozolomide, the order of the cell lines, from
most resistant to most sensitive, is: #16, 14, 23, 21, 6, 20, 17, 11, 5, and 4. This is
almost exactly the same order as the one they are in for the temozolomide growth
inhibition dose-response curves. From these observations we can conclude that
temozolomide and MNNG have very similar cytotoxic powers.
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Figure 10: Survival curves for the 24 cell lines after temozolomide treatment
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Figure 11: Survival curves for the 24 cell lines after MNNG treatment
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3. Dose response profiles for MNNG and temozolomide are different than with
BCNU
The advantage of a dose response curve is that is allows us to see the killing
profiles of each cell line. This high-throughput growth inhibition assay had already
been conducted in the Samson lab using the DNA damaging drug BCNU (figure 12) 5.
The profiles in that case were similar in all the cell lines: linear when plotted on a
log scale. For temozolomide and MNNG however, beyond displaying different
absolute sensitivities at any given dose, the twenty-four cell lines also display
different profiles for their dose response curves (all curves are plotted in log scale).
Furthermore, for each cell line tested for MNNG and for temozolomide sensitivity,
the profiles are the same with both drugs. For some (e.g. #6 and #1), the slopes are
very steep for the lower doses, and then the curves reach a plateau. For others (e.g.
#11), the slope is very gentle for the lower doses, and then becomes steeper as the
dose increases. Finally, some cell lines (e.g. #5) have a linear dose response. We can
conclude that for both drugs, the cells solicit the same DDR mechanisms as the
amount of damage increases. These are not the same mechanisms that are solicited
in response to BCNU induced damage.
4. The high-throughput assay was able to capture the cell cycle effects of
temozolomide or MNNG treatment on the cells:
Our flow cytometry plots show that as the doses of drug (whether it be
MNNG or temozolomide) increase, the total number of live cells decreases. The plots
also reveal that for all cell lines, increasing doses of drug lead to a rise in the fraction
of cells in late S and G2/M phase of the first cell cycle. This fraction corresponds to
cells that did not divide during their time in BrdU, and instead stayed arrested in
G2/M or late S (figure 13).
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Figure 12: Survival curves for the 24 cell lines after BCNU treatment (by
Chandni Valiathan)
Survival curves for the panel of 24 genetically varied cell lines for BCNU doses of 0,
10, 20, 40, 60 and 80 IAM. Graphs were obtained by Chandni Valiathan, using the
growth inhibition assay described earlier
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Figure 13: The high-throughput assay was able to capture the cell cycle effects
of temozolomide or MNNG treatment on the cells
- Representative example of the gated PI-Area vs. Hoechst-Area data for cell line #5,
at doses 0, 30, 60, 120, 240, and 480tM of temozolomide.
- The cells that are in the late G2/M phase of the first cell cycle are boxed. The
percentage of all cells that they represent is indicated in the box.
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2. Sister chromatid exchange assay
Introduction:
We used a high-throughput FACS based assay to measure the relative
amounts of growth inhibition of the Coriell panel of cell lines after treatment with
temozolomide. However, growth inhibition is only one of many DNA damage
endpoints. Indeed, while this assay gives us a good idea of which cell lines die or
arrest most after alkylation damage, it does not tell us how the other damage coping
mechanisms are being solicited in each cell line.
One way cells can bypass DNA damage is through homologous
recombination4 9. Temozolomide induced damage can lead to a futile repair cycle
that is unable to remove the damaged 06-methylguanine in 06-methylguanine-
Thymine mismatches. This eventually leads to double strand breaks. Furthermore,
the close accumulation of DNA nicks and abasic sites due to base excision repair and
nucleotide excision repair can also eventually lead to double strand breaks (DSBs)
in the DNA. Homologous recombination (HR) is one of the most common ways a cell
can repair these DSBs.
We wanted to measure the amounts of homologous recombination in the
Coriell set of cell line in order to determine whether or not amounts of HR always
correlated with amount of growth inhibition post temozolomide induced damage.
One would expect that a sensitive cell line would have very strong growth inhibition
post treatment, while having high amounts of homologous recombination. However,
a particular cell line could be very sensitive to the damage as far as growth
inhibition goes, and have very low amount of HR, indicating that the cell death
process is the more solicited response. For the resistant cell lines, some could have
low growth inhibition post damage and low amounts of homologous
recombination-indicating that the cells repair the damaged bases very efficiently
before they lead to DSBs or signal for cell death. However, other resistant cell lines
could have low growth inhibition post damage with high amounts of HR. These cell
lines would be strongly soliciting HR in order to avoid cellular death or senescence.
Distinctive homologous recombination (HR) pathways exist, such as
synthesis-dependent strand annealing (SDSA) and double-strand break repair
(DSBR). After DSB formation, the DNA ends are resected to form 3 single-strand
DNA (ssDNA) overhangs. The HR protein machinery then executes strand invasion
of a partner chromosome. After a successful homology search, strand invasion
occurs to form a D-loop structure. DNA synthesis then ensues. In the SDSA pathway,
the D loop is unwound and the freed ssDNA strand anneals with the complementary
ssDNA strand that is associated with the other DSB end. The reaction is completed
by gap-filling DNA synthesis and ligation. Only noncrossover products are formed.
Alternatively, the second DSB end can be captured to form an intermediate that
harbors two Holliday junctions (HJs), accompanied by gap-filling DNA synthesis and
ligation (figure 14). The resolution of HJs can result in either noncrossover or
crossover products 1.
The sister chromatid exchange assay uses the fact that BrdU can incorporate
into the DNA of actively replicating cells to measure the amounts of crossover
products induced by homologous recombination. The number of these crossover
products is considered to be a surrogate marker for the overall amount of
homologous recombination5-s 1. In the SCE assay, cells-treated or not with
different doses of temozolomide-are left to proliferates with BrdU in their media
for the duration of two cell doubling times. As the cells replicate, BrdU is
incorporated into the newly synthesized DNA, instead of thymine. Therefore, after a
first round of replication, the cells contain DNA that has one strand that contains
BrdU and another that does not. The cells then replicate their DNA a second time.
Right before dividing again, they have paired sister chromatids in which one
chromatid has BrdU incorporated into both strands, and the other has BrdU
incorporated into only one of two strands (figure 15). For our experiments, it is at
that moment that we arrested our cells in metaphase, and made metaphase spreads
to visualize the sister chromatids.
Hoechst dye preferentially binds AT-rich regions in the DNA, and is quenched
by BrdU; we therefore used Hoechst dye to stain our cells' chromosomes. As a result,
the sister chromatids were differentially stained, with the sister chromatid that had
BrdU incorporated into both strands being lighter5 2. This allowed us to visualize all
the crossover events that happened during the second round of DNA replication.
Indeed, such crossover events result in "harlequin" stained chromosomes, as shown
in figure 16.
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Figure 15: Schematic representation of BrdU incorporation into the DNA of
replicating cells
DNA strands that have incorporated BrdU are represented in pink, those that have
not are represented in blue.
Chromatids that have incorporated BrdU into both strands are lighter after our
staining step than the ones that have incorporated BrdU into only one of two strands.
Figure 16: Representative picture of a metaphase spread obtained with our
SCE assay
This black and white picture shows one of the metaphase spreads that were found
for cell line #8 at a dose of 120pM. The read arrows indicate sites where a sister
chromatid exchange occurred.
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Results and Discussion:
1. Results with the TK6 and TK6 + MGMT cell lines
We treated our cells with temozolomide. We used a dose range of 0 to 120ptM
for the Coriell panel of cell lines, and a range of 0 to 30 [M for the TK6 cell line
(figure 17).
Temozolomide's main cytotoxic lesions are 0 6MeG and 3MeA. A frontline
repair pathway used by cells to repair the induced damage is direct removal of the
methyl adducts with the enzyme 06-methylguanine-DNA methyltransferase. MGMT.
It has previously been reported that cells lacking MGMT are particularly sensitive to
such alkylating agents. It is therefore not surprising that the B lymphoblastoid cell
line TK6, which lacks MGMT, has very high amounts of temozolomide-induced SCE's.
In fact, in was not possible to obtain a sufficient amount of metaphase spreads to
reliably measure SCEs for doses higher that 30pM. We also performed the assay on
the TK6 + MGMT cell line. This is a TK6 cell line in which MGMT has been
reconstituted and is overexpressed. Not surprisingly, the TK6 + MGMT cell line is
very resistant to SCE induction through temozolomide treatment. The levels of
induced SCE's are baseline for doses up to 120pM.
2. Broad range of sensitivity for the Coriell panel of cell lines
The Coriell panel of cell lines displayed a broad range of sensitivity to
temozolomide for the growth inhibition assay. Similarly, the cell lines display a
broad range of sensitivity for the SCE assay. The TK6 cell line had the highest
induction of SCEs. For the Coriell cell lines, the number of SCEs at the 120 pM dose of
temozolomide ranged from 0.006 SCE's per chromosome (cell line #22) to 0.65
SCE's per chromosome (cell line #4). This represents a 100 fold range.
3. Number of induced SCEs generally correlates with the cell lines' growth inhibition
profiles
Most of the cell lines' growth inhibition dose response profiles correlated
strongly to their SCE induction results. Cell lines #4 and #5 were the two most
sensitive cell lines in the growth inhibition assay, with #4 being more sensitive than
#5. This was also observed for the SCE endpoint: #4, then #5, are the two cell lines
with the highest amounts of induced SCE's per chromosome at any dose.
Furthermore, cell lines #22 and #8 were among the most resistant in the growth
inhibition assay, and they were also among the most resistant in the SCE assay. In
general, most of the cell lines' sensitivities for the growth inhibition endpoint
correlated with their sensitivities for the SCE endpoint.
From these observations we can infer that, for the cell lines tested, sensitivity
to temozolomide, as far as growth inhibition in concerned, correlates to high
amounts of induced SCE's, while resistance correlates with low amounts of induced
SCE's.
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Figure 17: Induced sister chromatid exchange rates for the 24 cell lines after
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Materials and Methods:
1. Tissue Culture
The 24 lymphoblastoid cell lines, established using EBV transformation, were
obtained from the Coriell Institute and were designated 1-24 as follows: #1
(GM15029), #2 (GM15036), #3 (GM15215), #4 (GM15223), #5 (GM15245), #6
(15,224), #7 (GM15236), #8 (GM15510), #9 (GM15213), #10 (GM15221), #11
(GM15227), #12 (GM15385), #13 (GM15590), #14 (GM15038), #15 (GM15056),
#16 (GM15072), #17 (GM15144), #18 (GM15216), #19 (GM15226), #20
(GM15242), #21 (GM15268), #22 (GM15324), #23 (GM15386), and #24
(GM15061).
These cell lines, as well as the lymphoblastoid cell line TK6, were grown in
suspension in RPMI medium supplemented with 15% fetal bovine serum, 1%
glutamine, and 1 % penicillin-streptomycin. All assay were set up using
logarithmically growing cells.
The 24 cell lines were ordered based on their normal doubling time, then
partitioned into four groups, as detailed in table 1 Cell lines in each group were
assayed based on the approximate doubling time for the group.
20 20
16 21
24 21
6 22
14 22
1 22
17 22
3 23
5 24
15 24
23 24
18 35
10
22
3740
Table 1: Doubling times for all 24 cell lines, and approximated doubling times
The cell lines were divided into four groups of lines with similar doubling times. The
assays were conducted using their approximated doubling times. This allowed us to
handle several cell lines at a time.
,
21 20
2. Flow cytometry based growth inhibition assay
Temozolomide treatment:
Cells were grown to mid-log phase. Cells were spun and resuspended in
serum-free media. 270 [d of cells at a density of 4.5x10 5 cells/ml were plated in
each well of one row of a V-bottom 96-well plate. If multiple cell lines were assayed,
each cell line was plated in one row of a 96-well plate.
The drug was diluted to loX of the final dose concentrations in serum-free
media in another 96-well plate. 30 d of the IOX drug was transferred to each well in
the 96-well plate containing cells, after which the cells were incubated at 37 0C for lh.
After lh, cells were spun down at 1500rpm for 5min. Drug-containing media was
removed and the cells were washed with 200[d warm 1XPBS per well. The cells
were then resuspended in 280uL of warm media containing serum, transferred to a
flat-bottom 96-well plate and incubated at 370C for the duration of two doubling
times.
MNNG treatment:
Cells were grown to mid-log phase. 270 tl of cells at a density of 2.5x10 5
cells/ml were plated in each well of one row of a flat-bottom 96-well plate. If
multiple cell lines were assayed, each cell line was plated in one row of a 96-well
plate.
The drug was diluted to lOOX of the final dose concentrations in serum-free
media in another 96-well plate. 3 1d of the IOOX drug was transferred to each well in
the 96-well plate containing cells. The cells were then incubated at 370C for the
duration of two doubling times.
BrdU addtion
After allowing cells to respond for two doubling times after drug treatment,
the cells are incubated in the presence of BrdU for another two doubling times. The
optimal BrdU concentration was determined to be 45pM for the Coriell cell lines as
well as for TK6.
A the first two doubling times, BrdU was added to the treated cells at a
concentration of 45 M (from a 10mM stock). BrdU was replenished every 12 hours
after this start, by adding an extra 45 tm to each well. This was done for the
duration of two more cell cycles.
Sample preparation for FACS
At the end of four doubling times after drug treatment, cells were transferred
to a V-bottom 96- well plate using a multi-channel pipette. The plate was spun down
at 1500rpm for 5min. The media was removed and cells were washed with 200 tL of
cold 1XPBS.
The cells were then resuspended in 280uL of lX lysis buffer (0.1M Tris HCI pH
7.5, 0.1% Igepal CA-60, 1mM CaCl2, 5mM MgC12, 0.2%BSA (w/v), 1.2 tg/ml Hoechst
33258 and lx104 chicken erythrocyte nuclei (CEN)/ml) and incubated on icefor 15
minutes. Two wells containing only the lysis/staining buffer and propidium iodide
are also prepared as blanks
Before running each sample, it was transferred to a flow cytometry tube, and
12 1 of 100 g/ml propidium iodide was added. Each sample was then briefly
vortexed, and analyzed on a BD LSR II flow cytometer.
Data Collection
Events were visualized on the side scatter vs. forward scatter plot to gate out
debris, and on the PI-height vs. PI-area plot to exclude doublets that fall below the
diagonal. The voltages for PI and Hoechst were adjusted to position the chicken
erythrocyte nuclei at the (30K, 30K) point to facilitate subsequent data analysis.
15 000 events that passed the two selection criteria were collected and viewed on a
PI- Area vs. Hoechst-Area plot.
Data Analysis
All data were analyzed using FlowJo software (TreeStar Inc). For each cell line
and drug dose, the debris and doublets were gated out. The remaining events were
observed on a PI-Area vs. Hoechst-Area plot. The regions corresponding to cells in
the 1st, 2nd or 3rd cell cycle post BrdU addition were gated. Hoechst fluorescence of
cells decreases as they incorporate BrdU during DNA replication. Therefore, as the
cells replicate and divide, they move from the region labeled 1st cell cycle to the
region labeled 2nd cell cycle, to the region labeled 3rd cell cycle. For each sample, the
number of events in each gate was determined. The CEN were also gated (around
30k, 30k) in order to normalize the number of cells in each sample.
The normalized fraction of proliferating cells post treatment is given by the
formula:
1/2 * (# of events in cell cycle 2) / # CEN + 1/3 * (# of events in cell cycle 3) / # CEN
The ratio of proliferated cells in a treated sample to that in an untreated
sample gives the % control growth value that is used to plot a survival curve.
3. Sister Chromatid Exchange assay
Temozolomide treatment
Cells were grown to mid-log phase. Cells were spun and resuspended in
5OmL Falcon tubes in 18mLs of serum-free media at a concentration of 5*10s
cells/mL. Each dose corresponded to one tube. The drug was diluted to 1oX the
final dose concentrations. 2mLs of 1oX drug was added to the corresponding dose
tube.
After lh, cells were spun down at 1500rpm for 5min. Drug-containing media
was removed and the cells were washed with 10mLs of warm 1XPBS. The cells
were then resuspended in 15mLs of serum containing media supplemented with
10M of bromodeoxyuridine (BrdU, 1:100 dilution of 1mM stock). The cells were
transferred to a 25cm3 cell culture flask and returned to the incubator for the
duration of 2 normal doubling times.
Obtaining metaphase spreads
After complete BrdU incubation, 0.1[tg/ml of Colcemid (1:1000 dilution of a
0.1mg/ml stock solution) was added to each flask and then left to incubate for 2
more hours. The contents of each flask were then transferred to a 15mL Falcon tube.
The cells were then spun at 100g for 5min. The supernatant was aspirated, leaving a
small volume of liquid remaining, in which the cells were then resuspended. 5mLs of
hypotonic solution were then added very slowly to each tube, drop by drop, in order
to avoid that the cells burst prematurely. The cells were then incubated in hypotonic
solution at 37C for 15min.
Following hypotonic treatment, the tubes were centrifuges for 5min. The
majority of the supernatant was aspirated, and the cell pellet resuspended in the
remaining volume as done previously. The cells were then slowly resuspended in 5
mLs of Carnoy's fixative (3 MeOH:1 Acetic Acid). The samples were again spun for
5min at 100g, the supernatant almost entirely aspirated and the cells resuspended
in the remaining liquid volume, and the cells slowly resuspended in 5mLs of
Carnoy's fixative. The cells were the spun 5min again, and the supernatant aspirated
leaving approximately 1mL of liquid in the tube to resuspend the cells in.
The cells were then dropped onto microscope slides, from a height of 12-18
inches, using a Pasteur pipette. 4-5 drops were placed on each slide. The slides were
left to dry overnight.
Harlequin staining of chromosomes
Slides were placed in coplin jars and stained for 20min in a 5 ig/ml Hoechst
solution (a 50tg/ml Hoechst stock solution was diluted 1:10 in 1x Sorensen's
phosphate buffer, itself made for a 1oX stock containing: 0.335M of Na2 HPO 4 and
0.335M of KH2 PO 4 ). The slides were then rinsed with water, blotted to remove
excess fluid, and left to air dry.
A few drops of 1X Sorensen's buffer was then dropped onto each slide, and
the slides were mounted with a rectangular coverslip. These slides were placed
onto a 650C slide warmer and exposed to black light for 20min.
After 20min under black light, the slides were taken off of the slide warmer.
The coverslips were removed, the slides rinsed with water, blotted to remove excess
water, and again left to air dry. A large drop of 20X SSC buffer (3M of NaCl and
300mM of sodium citrate in water) was placed onto each slide, the slides mounted
with a rectangular coverslip, and placed back onto a 650C slide warmer for an
additional 20min.
The slides were then taken off of the slide warmer, and rinsed after their
coverslips were removed. The excess water was blotted and the slides were left to
air dry. The slides were incubated for 8min in 5% Giemsa staining solution (1:20
dilution in Sorensen's buffer), then rinsed with water, and left to dry fully.
The slides were dipped in histological grade xylene, then two or three drops of
Permount mounting solution was placed on each slide, and they were mounted with
a rectangular coverslip and left to dry completely.
Microscopy and image analysis
Spreads were scanned with bright field microscopy at a low power (10, 20x)
to first find second division cells. During replication the cells incorporated the BrdU
into their newly synthesized DNA. Therefore at the metaphase of the first cellular
division, sister chromatids both contain one strand that has incorporated BrdU
(figure 15). At the metaphase of the second cell division, one sister chromatid has
only one strand that has incorporated BrdU, while the second has incorporated it
into both strands (figure 15). In second division cells the Hoechst fluorescence of
two sister chromatids will therefore be different. After Giemsa staining this
translates into one chromatid stained dark purple or pink, with the sister chromatid
stained a lighter pink (figure 16).
20 second division metaphase spreads were then photographed at a power
of 100x. For each spread the number of chromosomes, and the number of exchanges
were counted using Imajej software. Then the average number of exchanges per
chromosome across all 20 spreads was calculated.
Conclusions and Future Directions
A few key results were shown in this thesis. We have first and foremost
shown-through the use of a high-throughput highly sensitive growth inhibition
assay with a broad range of sensitivity-that while our Coriell panel of cell lines
display a very broad range of sensitivity to MNNG and temozolomide, their relative
sensitivities to both drugs are very similar. Several conclusions can be drawn from
this observation. First of all, the implicit assumption that temozolomide and MNNG
are so similar in their mode of toxicity that they can be used and referred to
interchangeably is not in contradiction with this study. Since MNNG has for a long
time been a key model alkylating agent for toxicity studies, while temozolomide is
being used in the clinic today, this apparent interchangeability is of great scientific
relevance. Second of all, since these cell lines were derived from different healthy
individuals, we can infer that this similarity in sensitivity ranking would also be
observed in these individuals. We can thus conclude that an approximation of an
individual's sensitivity to MNNG can be determined by examining in a large
population his or her relative sensitivity to temozolomide, as well as the sensitivities
of that population to MNNG (and vice-versa).
In most of the cell lines we tested, there was a positive correlation between
the sensitivity to growth inhibition and the sensitivity to SCE induction. This is
consistent with the idea that if a cell line is sensitive, it is more likely to accumulate
damage that processes such as homologous recombination will mediate. We did
however find one cell line that was quite sensitive to temozolomide as far as growth
inhibition goes, all the while having very low amounts of induced SCEs. We can
conclude that this cell line resorts to cell death and cell cycle arrest but not as much
to homologous recombination.
Some supplementary studies would be needed to strengthen our conclusions.
Testing larger numbers of individuals, or cell lines derived from individuals, would
provide more statistical confidence that a given individual's sensitivities to
temozolomide and MNNG are similar. As for the SCE's induced by temozolomide,
while for the sensitive cell lines it is difficult to obtain second division metaphase
spreads for doses higher than 120tM, it would be of interest to examine the induced
SCEs for doses larger than 120tM in the resistant cell lines. Indeed this would allow
us to further distinguish and rank the SCE resistant individuals among themselves.
While these DNA damage phenotypes reveal important information in
themselves, it is their correlation to systems-wide data that would make it possible
to predict the sensitivity of yet unstudied cell lines to temozolomide and MNNG.
Furthermore, a systems-wide study would also allow us to gain insight into what
makes some cell lines sensitive for one DNA damage endpoint (e.g. growth
inhibition) and not another (e.g. homologous recombination). This systems-wide
data could be proteomic, transcriptomic (mRNAs, miRNAs, etc...), genetic, or
epigenetic. Since DNA damage solicits a very broad response that involves multiple
processes in the cell, one could imagine that several genome wide datasets of
different types, taken separately, could have predictive value. Finally, integrating
these genome-wide datasets could provide even more predictive strength.
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